InsiderPulse
Dashboard

PTCT

PTC Therapeutics, Inc.

Health CareRussell 2000

PTC Therapeutics, Inc. insider trading

PTC Therapeutics, Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in Warren, NJ. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent PTCT insider transactions

6 insiders traded PTCT on the open market between Jul 07, 2026 and Sep 17, 2026 — 24 sales worth $9.5M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$9.5M

24 of 24 on a 10b5-1 plan

Net
−$9.5M
Insiders
6

Open-market purchases (code P) and sales (code S) from PTC Therapeutics, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every PTCT Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

PTCT insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 13 insiders traded PTCT on the open market: 0 purchases and 284 sales worth $78.1M, 278 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 211 sales ($58.6M), by 12 insiders.

QuarterBoughtSold
Q2 2026—−$14.2M35 sales · all on a plan
Q1 2026—−$9.3M62 sales · all on a plan
Q4 2025—−$27.4M91 sales · all on a plan
Q3 2025—−$7.7M23 sales · 21 on a plan
Q2 2025—−$308.5K4 sales · 2 on a plan
Q1 2025—−$7.8M45 sales · 43 on a plan
Q4 2024—−$11.3M23 sales · all on a plan
Q3 2024—−$77.2K1 sale · all on a plan
Largest sale
−$4.4M of PTCT by Boulding Mark Elliott (Exec. VP And CLO) on Dec 02, 2024, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Almstead Neil Gregory10b5-1

    Chief Technical Ops Officer

    −$658K

    Jun 26, 2026

    7,718 sh · $85.26

  • Almstead Neil Gregory10b5-1

    Chief Technical Ops Officer

    −$35.1K

    Jun 26, 2026

    412 sh · $85.23

  • Almstead Neil Gregory10b5-1

    Chief Technical Ops Officer

    −$980.8K

    Jun 25, 2026

    11,337 sh · $86.51

  • Almstead Neil Gregory10b5-1

    Chief Technical Ops Officer

    −$726.6K

    Jun 25, 2026

    8,522 sh · $85.26

  • Almstead Neil Gregory10b5-1

    Chief Technical Ops Officer

    −$49.6K

    Jun 25, 2026

    582 sh · $85.24

  • Almstead Neil Gregory10b5-1

    Chief Technical Ops Officer

    −$36.2K

    Jun 25, 2026

    419 sh · $86.39

  • Almstead Neil Gregory10b5-1

    Chief Technical Ops Officer

    −$8.7K

    Jun 25, 2026

    100 sh · $87.00

  • Almstead Neil Gregory10b5-1

    Chief Technical Ops Officer

    −$418.5K

    Jun 24, 2026

    4,922 sh · $85.03

  • Almstead Neil Gregory10b5-1

    Chief Technical Ops Officer

    −$34.1K

    Jun 24, 2026

    401 sh · $85.01

  • Almstead Neil Gregory10b5-1

    Chief Technical Ops Officer

    −$977.8K

    Jun 22, 2026

    12,130 sh · $80.61

  • Almstead Neil Gregory10b5-1

    Chief Technical Ops Officer

    −$943.6K

    Jun 22, 2026

    11,619 sh · $81.21

  • Utter Christine Marie10b5-1

    SVP, Chief Accounting Officer

    −$1.5M

    Jun 17, 2026

    19,686 sh · $75.56

  • Boulding Mark Elliott10b5-1

    Exec. VP And CLO

    −$518.1K

    Jun 17, 2026

    6,600 sh · $78.50

  • Boulding Mark Elliott10b5-1

    Exec. VP And CLO

    −$146.6K

    Jun 17, 2026

    1,850 sh · $79.24

  • Boulding Mark Elliott10b5-1

    Exec. VP And CLO

    −$133.7K

    Jun 17, 2026

    1,703 sh · $78.50

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

PTC Therapeutics, Inc. company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
Warren, NJ
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001070081

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought PTCT

What the stock actually did in the 90 days following each open-market purchase

Don't check PTCT — let it ping you

Get told the moment an insider moves on PTCT

Pro watches PTC Therapeutics, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add PTCT to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track PTCT on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read PTCT insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

MEDPDNLIVEEVTEMALKSAPLSARVNBBIOCYTKDAWNDYNIMVT
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are PTCT insiders buying or selling?
Between Jul 07, 2026 and Sep 17, 2026, 6 PTC Therapeutics, Inc. insiders made no open-market purchases and 24 sales worth $9.5M, a net sale of $9.5M. 24 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much PTCT stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 13 PTC Therapeutics, Inc. insiders made no open-market purchases and 284 sales worth $78.1M. 278 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 211 sales ($58.6M). The largest sale was Boulding Mark Elliott selling $4.4M on Dec 02, 2024.
What was the largest recent PTCT insider trade?
Smith Mary L. (Director) sold $900K of PTCT stock on Jul 09, 2026 at about $90.00 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy PTCT shares?
No open-market purchase by a PTC Therapeutics, Inc. insider appears in the filings from Jul 07, 2026 to Sep 17, 2026 — every recorded open-market transaction in that period was a sale.
Where does PTCT insider trading data come from?
From the Form 4 filings PTC Therapeutics, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.